PC Detect - Panacea Global, Inc

P
G
Cancer Detection Services
P C D e t e c t SM
A new and sensitive diagnostic test for the detection
of prostate cancer.
Please Contact
Dr. Mahmood Moshiri
President/CEO
330 Highway 7 East
Suite 502
Richmond Hill ON
Canada L4B 3P8
P: 905-881-1049
F: 905-881-2241
www.panaceaglobalinc.com
Cancer Detection Services
PC Detect®
Cancer as a disease is one of the world's worst public health and financial problems. Statistics from
the American Cancer Society for 2004 indicate that an estimated 1.4 million people were diagnosed
with cancer in the U.S. and 564,000 people or about 1,500 people a day, are expected to die of
cancer this year in the U.S. alone.
Cancer Diagnostics—HAAH also has great potential to serve as a biomarker for cancer
diagnosis and monitoring as well as in treatment follow-up. Again the specificity of HAAH overexpression for cancer and its presence in a broad spectrum of cancer types are highly significant and
beneficial for its utility as a tumor marker. Panacea has developed methods to determine HAAH
levels at both the gene expression (mRNA) and protein expression levels.
HAAH can enhance the detection of cancer in tissue biopsies and can be prognostic for
disease severity. Methods have been developed at the Company to stain human tissues with antiHAAH antibodies, identifying the presence of cancer cells in the tissue sample. In one study utilizing
this methodology, HAAH protein expression was identified in resected tissue from individuals with
cholangiocarcinoma. Significantly, the levels of HAAH expression in this resected tissue directly
correlated with patient survival time, indicating that HAAH expression level measured in this fashion
may be useful in determining a patient’s prognosis and in tailoring therapy accordingly.
HAAH expression is upregulated at the gene expression level in cancer and this increased
expression may serve as the basis for a highly sensitive test for diagnosis and monitoring of
disease as well as the measurement of drug efficacy. The Company has developed a highly
sensitive qRT-PCR molecular diagnostic test to measure the expression of HAAH at the mRNA level.
This test is capable of detecting one cancer cell in a background of 50,000 normal cells and thus has
potential application for the measurement of minimal residual disease in various blood cancers (e.g.
acute myeloid leukemia). Furthermore, the Company has demonstrated that HAAH over expression
is itself regulated in certain cancers by signaling pathways that are downstream of tyrosine kinase
activities. Tyrosine kinase inhibitors (e.g. Gleevec, Sutent, Nexavar and Tarceva) have emerged as
potent anti-cancer agents. However, many of these drugs are only efficacious in a subset of cancers
and in a number of cases patients develop resistance to these drugs. As such a mechanism by
which one can determine the potential efficacy of a tyrosine kinase inhibitor in an individual patient
prior to its use is highly desired. Panacea has developed just such a test by monitoring the
expression of HAAH upon treatment of a patient’s cells in vitro with the drug. An efficacious drug
leads to a down-regulation of HAAH expression.
HAAH is found in the serum of cancer patients and is a biomarker for disease. The Company
has demonstrated that the HAAH protein is shed in the blood through an as-yet poorly understood
mechanism. The presence of HAAH in an individual’s serum has been shown to correlate with the
presence of cancer. Panacea has developed a simple assay to monitor HAAH levels in patient sera.
This assay has broad application for screening of individuals for initial detection as well as recurrence
of many different kinds of cancers including some for which currently no other biomarker exists.
Anti-HAAH antibodies may hold significant potential for in vivo imaging of tumors. The
localization of HAAH to the cellular surface of tumor cells and its consequent accessibility to
antibodies suggests its potential for use as target for imaging enhancing agents. Radio-labeling of
anti-HAAH antibodies and their incorporation into various radiological tests may provide significant
advantages for the localization of tumor masses and the identification of micro-metastases.
Anti-HAAH antibodies may also hold significant potential for identification and isolation of
circulating cancer cells. The detection of circulating tumor cells has been proposed as a method to
assess response to treatment of metastatic breast cancer. The detection of tumor cells may also have
clinical utility in risk stratification in early breast cancer, in early detection of relapse and in monitoring
the response to treatment. The presence of circulating tumor cells in patients with metastatic
carcinoma is associated with short survival. Technical advances have facilitated the detection of rare
circulating tumor cells. These cells appear to have characteristics of tumor cells and may be
identified in the peripheral blood of patients with cancer. The techniques have been used to detect
circulating tumor cells include cytometric and nucleic acid based approaches. The cytometric
1
PC Detect®
Cancer Detection Services
approaches use
HAAH Over-Expression in Cancer by IHC
immunocytochemical
methods to identify and
HAAH has been detected in all
characterize the individual
cancer types tested (n>20)
including: liver, bile duct, lung,
tumor cells. Nucleic acid
breast, prostate, colon, ovary,
based approaches detect
pancreas and in nearly 100% of
the DNA and RNA
all cancer specimens (n>1,000)
sequences that are
differentially expressed in
HAAH was not detected in over
tumor cells and normal
500 non-cancerous tissues
including proliferative disorders
blood components. A kit
currently marketed by
Staining for HAAH is found
Johnson & Johnson
throughout the cancerous tissue
involves a technique of
but is generally more prominent
Cancerous and Normal Bile Duct
mixing a blood sample
at the infiltrating margins of the
with iron particles coated
tumor
with an antibody that
Expression of HAAH can be
attaches to epithelial cells.
detected at both the genetic and
The epithelial cells are
protein levels
then distinguished from
leukocytes by antibodies
that have been tagged with a fluorescent dye so that the cancer cells can be easily distinguished and
counted. Since epithelial cells are not usually found in the blood, these cells are likely cancerous cells
from the breast tumor. This technique has been shown to distinguish carcinoma cells from other
blood cells, and recovery of the breast carcinoma cells is 75–100 percent. Another system is an
enhanced density gradient system that combines density gradient centrifugation and the immunobased techniques. This system is not approved by the U.S. FDA and is available only for research
purposes. Anti-HAAH antibodies may have utility in systems and kits to identify and isolate a broad
range of circulating tumor cells.
‹
Leukemia
Lung Carcinoma
Breast Cancer
Pancreatic Cancer
‹
‹
‹
Cholangiocarcinoma
Normal Bile Duct
Proliferating
Sclerosing
Cholangitis (PSC)
Confidential
Panacea Laboratories was established in 2006 to provide blood, serum, and tissue tests to diagnose
and monitor cancer. The facilities are fully compliant with the requirements of the Clinical Laboratory
Improvement Amendments of 1988 (CLIA).
CLIA established quality standards for laboratory testing to ensure the accuracy, reliability, and
timeliness of patient test results. CLIA requires that any facility examining human specimens for
diagnosis, prevention, treatment of a disease or for assessment of health must register with the U.S.
Centers for Medicare & Medicaid Services and obtain CLIA certification. CLIA-certified laboratories
are required to have documented standard operating procedures (SOPs), and procedures for sample
receiving and handling, result reporting, confidentiality, billing and training of technical staff. CLIA
specifies quality standards for proficiency testing, patient test management, quality control, personnel
and quality assurance.
Three categories of tests have been established: waived complexity, moderate complexity, including
the subcategory of provider-performed microscopy, and high complexity. Tests performed by a CLIAcertified laboratory, such as those performed by Panacea Laboratories, do not require prior approval
by the U.S. FDA.
To date, marketing and promotion of tests performed by Panacea Laboratories has been conducted
primarily through attendance and exhibiting at scientific and clinical meetings relevant to oncologists
and urologists. A dedicated website (www.panacea-labs.com) has been established to provide
information to both physicians and consumers concerning tests performed by Panacea Laboratories.
Beginning in mid-2007, efforts were initiated to establish partnerships with local laboratories around
the U.S. to collect patient samples for shipment to Panacea, where testing will be performed. Results
will be reported to the ordering physicians upon completion of testing. These local laboratories will
2
PC Detect®
Cancer Detection Services
also be responsible for marketing of Panacea’s tests to local physicians. Similar partnerships are
also being pursued with laboratories outside the U.S.
®
PC Detect is an ELISA assay measuring serum levels of HAAH to help determine the likelihood
®
that a patient has prostate cancer. PC Detect is recommended for men who have an elevated
prostate specific antigen
Serum HAAH Concentration in Prostate Cancer
(PSA) and/or an abnormal
digital rectal exam (DRE).
130
®
®
from PC Detect should be
interpreted in conjunction
with the patient's PSA level,
DRE, and medical and family
history. Prostate biopsy is
necessary for a definitive
diagnosis of cancer.
The excellent sensitivity and
®
specificity of PC Detect
across a range of PSA levels
has been demonstrated using
samples from 233 men with
biopsy-proven prostate cancer.
110
90
70
HAAH
PC Detect provides
information to differentiate
prostate cancer from benign
conditions and to help guide
patient management. Low
levels of HAAH as seen in
normal men may obviate the
need for biopsy. The results
50
30
10
-10
Non-Cancer*
PSA <2
PSA 2-4
PSA >4
n = 43
x =0
n = 100
x = 23.0
n = 49
x = 21.1
n = 84
x = 31.60
Prostate Cancer
n = 233, x = 25.7
Specificity = 93%
Sensitivity = 95%
* Men >50 years of age, cancer-free
®
PC Detect is currently available from Panacea Laboratories. In addition, Panacea is seeking FDA
approval of this test to permit wider marketing and use in the U.S. A prospective, multi-center clinical
®
trial to evaluate the diagnostic performance of PC Detect for prostate cancer screening in 600 men
recommended to undergo prostate biopsy was fully enrolled earlier this year. Data from this clinical
trial will be submitted in early 2008 as part of a PreMarket Approval (PMA) application to the U.S.
FDA, to facilitate development of a diagnostic kit and subsequent marketing to laboratories across the
®
U.S. Panacea anticipates completion of an out-licensing deal for development of a PC Detect kit
®
with one or more large manufacturers of diagnostic tests in 2008. PC Detect is indicated for the
measurement of serum HAAH levels in conjunction with the quantitative measurement of PSA and a
DRE, as an aid in the detection of early prostate cancer in men aged 50 years and older.
The American Cancer Society (ACS) recommends a PSA blood test and DRE yearly, beginning at
age 50, for men who have at least a 10-year life expectancy. Men at high risk, such as African
Americans and men who have a first-degree relative (father, brother, or son) diagnosed with prostate
cancer at an early age (younger than age 65), should begin testing at age 45. Men at even higher risk
(because they have several first-degree relatives who had prostate cancer at an early age) are
recommended to begin testing at age 40. Depending on the results of this initial test, further testing
might not be needed until age 45. The American Urological Association (AUA) endorses the
screening parameters of the ACS, including the fact that men with risk factors should be offered
testing at an earlier age.
In current clinical practice, prostate biopsy is recommended for men with a suspicious DRE result
regardless of the PSA level. According to the ACS, patients with a PSA > 10ng/mL are also
recommended to have a biopsy since more than 50 percent of these men have been found to have
3
PC Detect®
Cancer Detection Services
biopsies positive for cancer. A biopsy may be recommended for a non-suspicious DRE result and a
PSA result of between 4-10ng/mL as 25 percent of these men will also be positive for prostate cancer.
A recent study analyzing the prevalence of prostate cancer in patients with PSA levels below 4.0
ng/ml found significant detection rates of 6.6 percent (<0.5 ng/ml), 10.1 percent (0.6-1.0 ng/ml), 17.0
percent (1.1–2.0 ng/ml), 23.9 percent (2.1-3.0 ng/ml) and 26.9 percent (3.1-4.0 ng/ml). Approximately
20 percent of prostate cancers with aggressive features are found in men whose PSA level is less
than 4 ng/ml. On the basis of these and other recent studies, it has now been suggested to consider
biopsy in patients with a PSA level as low as 2.5 ng/ml. The PSA level can be used as a guide in
clinical practice but has limitations. As noted in the observations cited, even though a significant
percentage of men with prostate cancer had PSA levels below 4.0 ng/ml, the negative biopsy rate of
more than 70 percent indicates that PSA is lacking in terms of specificity and sensitivity, thus making
it an unreliable tool as a tumor marker. As well, high levels of PSA are common in benign conditions
of the prostate.
The DRE is also used as an assessment of abnormalities in the prostate and is performed to further
assess the patient for possible voiding dysfunction as well as to detect possible cancer. A suspicious
area palpated during the examination usually leads to a recommendation for a biopsy in order to
establish a more definitive diagnosis.
®
PC Detect used in conjunction with PSA and DRE has the potential to improve the specificity of
prostate cancer screening tests and thus reduce the number of men undergoing unnecessary biopsy,
which will result in reducing potential patient morbidity as well as achieving health care cost savings.
A positive test result may be due to other cancers or occasionally may have unknown causes.
Patients who have very small foci of cancer in their prostates ,may have serum HAAH levels in the
normal range. In such cases, physicians may recommend “watchful waiting” rather than immediate
®
treatment and may find it useful to monitor the patient’s cancer with frequent repeat PC Detect
testing.
®
Panacea Laboratories developed PC Detect and has determined its analytical performance
characteristics. Panacea Laboratories is certified under the Clinical Laboratory Improvement
Amendments of 1988 (CLIA) to perform high-complexity testing such as this immunoassay.
HAAH function is consistent with cancer etiology. HAAH is an enzyme that catalyzes the βhydroxylation of aspartyl or asparaginyl residues in EGF-like domains found in a number of proteins
involved in important cellular signaling pathways as well as in several proteins that interact with the
extracellular matrix. Both of these types of proteins have been demonstrated to play important roles
in the development and maintenance of the cancer cell and this subtle modification due to HAAH
activity can have profound effects on protein function. One important example is the Notch signaling
pathway which is known to affect cell fate decisions and growth control during cellular maturation.
Notch has 17 EGF-like domains and is involved in cancer phenotypes such as proliferation, motility
and invasiveness effecting tumor growth and metastatic potential. A direct interaction between
Notch and HAAH has been demonstrated in tumor cells.
HAAH has been demonstrated to be sufficient to induce a cancer cell phenotype. When over
expression of the HAAH gene is induced in otherwise normal cells, these cells become cancerous as
judged by their phenotypic properties in vitro. Specifically the transformed cells have increased rates
of proliferation, loss of contact inhibition and enhanced motility and invasiveness. More importantly
these transformed cells form solid tumors when injected into animals. Conversely, when cancer cells
are treated to inhibit HAAH over-expression, the cancer cells revert to a normal phenotype as
measured by these same standard criteria.
HAAH is over-expressed specifically by tumor cells and is not required for normal cell
function. Although initially identified in liver cancer, increased expression of cell-surface HAAH has
been observed in more than twenty different cancers, including both solid tumors and blood cancers.
4
Cancer Detection Services
PC Detect
®
The over-expression of HAAH is not associated with any normal tissues in children and adults with
the exception of placental trophoblastic tissue where HAAH is thought to be involved in implantation
in the uterine wall. HAAH is important for the maintenance of the tumor cell phenotype, as described
above, but not required for normal cellular function. This is evidenced by the creation of transgenic
mice in which the murine equivalent of the HAAH gene was “knocked-out” such that the animals did
not express HAAH. These animals were “normal” except for two features; they had several physical
developmental deficits (e.g. shortened snout, palate defects and fused digits) and they displayed
reduced levels of fertility. Interestingly, this phenotype is consistent with the effects of knock-out
mutations of Notch in mice. Importantly, these developmental abnormalities are not relevant to
treatment of already developed mice (or people.)
HAAH is expressed on the surface of cancer cells. In normal cells, HAAH is generally expressed
at very low levels exclusively in the endoplasmic reticulum (ER) of the cell. Thus the protein is only
found within the cell. In tumor cells, HAAH over-expression leads to a translocation of the protein
from the internal compartment of the ER to the cellular surface. This translocation results in the
approximation of HAAH to its potential substrates such as Notch, a cell surface receptor, and
tenascin, a component of the extra-cellular matrix. Surface expression of HAAH also makes it
accessible to drugs or antibodies that are not capable of crossing cellular membranes.
Thus, several unique attributes of HAAH make it an extremely promising anti-cancer therapeutic
target:
HAAH plays an important role in the promotion, proliferation, motility, invasiveness and
metastasis of tumors. Therefore targeting the HAAH protein is likely to have a direct effect on
the very processes that characterize malignancy.
Increased expression of HAAH is specific to tumor cells and the enzyme is not necessary for
normal cell function. Thus, targeting HAAH will decrease only tumor cell function and should
not cause any adverse effects in normal tissues.
HAAH over-expression has been observed in more than twenty different cancers. This
feature suggests that anti-HAAH therapy which is developed for a single cancer type, will be
effective in other types of cancer
HAAH is expressed on the surface of cancer cells making it accessible from outside the cell.
This attribute opens up the potential for the use of anti-HAAH antibodies as therapeutic
agents. Antibodies that do not cross cellular membranes, but interact with membrane
proteins, have demonstrated great potential as druggable agents in oncology and other
disease states.
Current Collaborations—Panacea has several corporate and academic collaborations
with the aim of advancing specific products toward commercialization and exploring new uses for
current technologies. These collaborations involve the provision of grant or contract support by
Panacea to collaborators, as well as support by collaborators provided to Panacea; the collaboration
with MDS Pharma Services, Inc. is totally supported by external grant funding provided to Panacea.
In addition, Panacea has obtained exclusive licenses to certain therapeutic, diagnostic and
manufacturing technologies from highly regarded academic collaborators.
Product/Technology
HAAH
HAAH
Collaborator
Brown University/Rhode Island
Hospital
Massachusetts Institute of Technology
HAAH
Catalent (formerly the Gala
Biosciences Division, Cardinal Health)
HAAH
Olympus
Focus
Exclusive world-wide license and collaboration
for therapeutic and diagnostic applications
Exclusive license option and collaboration to
develop human anti-HAAH monoclonal
antibodies
Scale-up, process development, and GMP
production of anti-HAAH monoclonal antibody
therapeutic
Development of HAAH-based ELISA assay for
cancer diagnostics tests
5
Cancer Detection Services
PC Detect®
Management and Board of Advisors
Mahmood Moshiri BS, MD, CPATH, APATH, FICN
President, Chief Executive Officer and Chief Medical Officer
Since 1990, Dr. Moshiri has been on faculty at several medical universities. Dr Moshiri has extensive
experience in teaching and practicing medicine and performing clinical research focused on preventive
medicine, cardiovascular health and cancer pathology. He has published extensively on the subject of
pathology in preventive and therapeutic disciplines during the last 20 years. Dr. Moshiri has hosted
numerous newscasts in the health and preventive fields for National TV. In addition to his media
expertise, his articles have been published in many American, European and Asian medical journals. He
has been a contributing author of medical books published in North America. Dr. Moshiri has
participated in numerous national and international conferences as an organizer, session chair, panelist,
invited lecturer and international speaker in many world Medical Congresses. Dr. Moshiri served as Vice
President of the International College of Nutrition and has received three Medical World Congress
Awards (1997 Banff, 2007 Alberta, and 2010 Egypt). Dr. Moshiri is an editorial board member of The
Open Neutriceutical Journal (USA) and he is also a member of the Board of Directors for Panacea
Laboratories Canada Inc., Proteus Imaging Canada Inc. , and Panacea Global Inc. , and Vice President
of Panacea Pharmaceutical, Inc. Dr. Moshiri is BS, MD, Pathologist.
Binnay Sethi
Vice President
Binnay Sethi is the Secretary and Director of Panacea Global, Inc. He is also the CEO of Binalli Vision,
one of the largest building maintenance companies in Canada. Binalli Vision has over 500 clients and
employs over 400 people. He founded the company in 1995 and has grown the organization from
inception. Throughout his career, Mr. Sethi has founded and managed numerous companies that deal
with building maintenance and real property administration. Mr. Sethi studied Business and International
business at York University and Seneca College.
Panacea Global is currently in the process of hiring an independent Board of Directors who will execute
the strategic plan of the company.
Hossein A. Ghanbari, Ph.D.
Dr. Ghanbari co-founded Panacea Pharmaceuticals, Inc. and serves as Chairman, CEO & Chief
Scientific Officer. Dr. Ghanbari worked at the world headquarters of Abbott Laboratories in Chicago,
Illinois for more than ten years, where he developed several pharmaceuticals and the first diagnostic test
for Alzheimer’s Disease test marketed in the world. He served on Abbott’s Technical Advisory Board and
was inducted into its Volwiler Society, a prestigious honorary organization that serves as Abbott’s
recognition of the highest standards of scientific accomplishment.
Prior to that, he was a co-founder and served as Senior Vice-President for Research & Development of
Molecular Geriatrics Corporation, a bio-pharmaceutical company that focused on developing drugs for
neurodegenerative diseases. He was also the Founder, CEO, & President of Medical Toolworks, which
was created to develop highly needed and innovative medical tools.
Dr. Ghanbari served as Senior Vice-President for Research & Development and Strategic Planning as
well as Director for four years at Nymox Pharmaceutical Corporation. He was instrumental in starting
Nymox (NASDAQ: NYMX), and was responsible for bringing in an array of technologies which have
established Nymox as an international presence in the area of Alzheimer’s diagnostics and therapeutics.
Dr. Ghanbari is the current Chairman of the Board of Alzheimer’s Corporation of Albuquerque, New
Mexico.
Professor Jack R. Wands, M.D.
Professor Jack R. Wands, M.D. is a Senior Consultant to the Company and Panacea Pharmaceuticals
collaborator at Rhode Island Hospital/Brown University. He is a highly respected and internationally
recognized scientist with more than 400 scientific publications, books, and abstracts. Dr. Wands is
currently Chief of the Division of Gastroenterology at Lifespan Rhode Island Academic Medical Center,
Director of the Liver Research Center, Professor of Medicine at Brown University School of Medicine,
and Head of the Gastroenterology Section at Brown University. He is an editorial board member of
Hepatology, International Hepatology Communications, Journal of Viral Hepatitis, and Viral Hepatitis
Reviews. He is an editorial consultant to several outstanding journals including the Journal of Clinical
6
Cancer Detection Services
PC Detect®
Investigation, New England Journal of Medicine, Proceedings of the National Academy of Sciences,
Journal of Infectious Disease, Gastroenterology, Journal of Virology, Virology, and Nature Medicine. Dr.
Wands has served as a consultant for nearly 20-years to both the World Health Organization and the
Pan American Health Organization.
Hon Elinor Caplan
Hon Elinor Caplan’s political career began as an elected Municipal Alderman in North York from 19781985. During that time she was chair of almost every major council committee. Elinor gained extensive
experience in municipal planning, transportation & human services. She served in the Peterson
Government as Minister of Government Services, Chair of Management Board & Chair of the Cabinet.
Elinor Caplan is best known as Federal MP for Thornhill (1997-2004); Elinor served as Parliamentary
Secretary to Minister of Health before In 2001 she was named Minister of National Revenue where she
had responsibility for Revenue Canada as well as Canada Customs. Elinor had responsibility for the
implementation of the Canada/USA Smart Border Accord. Her recommendation to establish the
Canadian Border Services Agency was accepted by Rt Hon Paul Martin. In late 2007 Elinor completed a
project for the World Health Organization (WHO) assisting with the development of an integrated Health
System & legislation in Armenia.
Professor Frank E. Young, M.D., Ph.D.
Professor Frank E. Young, M.D., Ph.D. is a Special Consultant in Corporate Development for the
Company. He was appointed Commissioner of the Food and Drug Administration in 1984 and held that
post until 1989, served as Deputy Assistant Secretary for Health, Science, and the Environment from
1989 to 1993, and Director of both the Office of Emergency Preparedness and The National Disaster
Medical System from 1993 to 1996. Prior to his public service with the U.S. government, Dr. Young held
faculty positions and memberships in a number of universities and research institutions. These include:
Case Western Reserve University; Scripps Clinic and Research Foundation; University of California at
San Diego; School of Medicine and Dentistry at the University of Rochester, New York; and Strong
Memorial Hospital, also located in Rochester. Dr. Young is a member of the Institute of Medicine of the
National Academy of Sciences. He has published over 200 scientific and public policy publications.
Hon David Caplan
David Caplan was first elected to the Ontario Legislative Assembly in September 1997 and was reelected in 1999, 2003 and 2007 to serve the residents of Don Valley East. As Minster, Caplan
established a four year province-wide strategy combating Diabetes; by creating a comprehensive
prevention and treatment system for diabetes and other chronic diseases; organizing and expanding
local access to care and support; providing tools and training to practitioners; and implementing
safeguards and measures to report on progress. He is spearheading the creation of the first stand-alone
infrastructure ministry in Canada. Under Caplan’s leadership, the Government of Ontario won three
prestigious urban planning awards recognizing the visionary Growth Plan for the Greater Golden
Horseshoe; a comprehensive 25 year strategy to maximize the benefits of population growth and
maintain a high quality of life for the fastest growing region in Canada. Caplan has also assumed
responsibility over major government agencies and key public assets, including the Ontario Realty
Corporation, Liquor Control Board of Ontario, Ontario Lottery and Gaming Corporation and the Toronto
Waterfront Revitalization Corporation.
Mehdi Hatamian, Ph.D.
Dr. Hatamian’s areas of expertise are high-speed VLSI signal processing, image processing, high
temperature superconductors, full-custom and low power circuit and architecture design, adaptive
filtering, high-density and high-speed CMOS design, and biomedical electronics. Dr. Hatamian has
published nearly 50 papers in his areas of expertise and holds 81 issued patents with several patents
pending. He is a Fellow member of the Institute of Electrical and Electronics Engineers (IEEE) whose
technical objectives center on advancing the theory and practice of electrical engineering, electronics,
computer engineering, and computer science. Election to the rank of Fellow is one of the IEEE’s most
prestigious honors. He received his Fellow award for his contribution to the design of high-performance
digital signal processors. Dr. Hatamian received the “#1 Patent Holder” award from Broadcom Corp. for
2005-06 and 2006-07, and the Broadcom Fellow award in 2011. He is the recipient of the University of
Michigan’s ECE Alumni Merit Award for 2008-09. He has participated in numerous national and
international conferences and other professional activities in his field as an organizer, session chair,
7
Cancer Detection Services
PC Detect®
panelist, invited lecturer, and moderator. He is also the co-founder of and the sole investor in the
following companies: Smart Medical Technologies, M&T Industries, and Dragon Tale Entertainment.
Dr. Hatamian received a B.S. degree in Electrical Engineering from Sharif University of Technology in
Tehran, Iran and a M.S. and Ph.D. degree in Electrical Engineering from the University of Michigan in
Ann Arbor.
Professor David Khayat, M.D.
Professor Khayat served as President of France’s Cancer National Institute from 2004 to 2006.. He has
published more than 500 papers in the field of oncology and clinical pharmacology. He is chevalier of
the National Order of Merit, of the Legion of Honor, of the Order of Sainte Agathe and the Academics
Palms. He is the Ambassador of the Republic of San Marino at UNESCO. Since 2002, he has been a
member of the “War on Cancer Plan” of Jacques Chirac. He organized French Oncologists through the
French Federation of Medical Oncologists (FFOM) and was elected its first President, a position he held
until 2001.
Professor Khayat is a member of the Clinical Research Committee of the AACR and received the AACR
Public Service Award in 2000 and a research grant from the Bristol Myers Squibb Foundation. He sits on
various French, European and International Committees and is one of the members of the steering
committee of the World Alliance of Cancer Research organization and the Associate Editor of the
Journal of Clinical Oncology and CancerHe is member of several scientific societies and has been a
member of ASCO since 1987.
Professor Eleftherios P. Diamandis, PhD
Dr. Diamandis is division head of clinical biochemistry in the department of pathology and laboratory
medicine at Mount Sinai Hospital; biochemist-in-chief at the University Health Network and Toronto
Medical Laboratories; and division head of clinical biochemistry in the department of laboratory medicine
and pathobiology at the University of Toronto in Ontario, Canada. Dr. Diamandis has been active in the
field of cancer diagnostics over the past 20 years. He currently chairs the National Academy of Clinical
Biochemistry effort to develop guidelines for the clinical use of tumor markers. His main research
interests are tumor markers, especially a group of enzymes called human tissue kallikreins. His most
recent research focuses on proteomic methodologies for identifying novel cancer biomarkers and the
physiology of kallikrein enzymes, as they relate to cancer initiation and progression. He is also
conducting research to validate multiparametric panels for early ovarian, breast, and prostate cancer
diagnosis. Dr. Diamandis serves on the boards of 25 journals. He has published more than 400 original
papers and holds 13 patents, with another 20 pending. He co-authored a recent textbook, Tumor
Markers. For many years, he has run workshops on tumor markers and proteomic technologies at the
AACC annual meetings
Carl R. Merril, M.D
Dr. Merril is a leading expert and innovator on employing non-biased approaches, such as highresolution two-dimensional protein electrophoresis, to search for abnormal biochemical pathways and
genomic alterations in diseases of unknown etiology that affect the central nervous system. He has
published more than 200 scientific papers, is an inventor on nearly two dozen patents, and has been the
recipient of numerous awards for his scientific and administrative achievements. Dr. Merril came to the
National Institutes of Health since 1963 and was most recently Chief, Laboratory of Biochemical
Genetics at the National Institute of Mental Health of the National Institutes of Health; he retired from
NIH in 2006. Dr. Merril is an Adjunct Professor in Biochemistry and Genetics at George Washington
University and an Adjunct member of the graduate faculty of the University of Maryland. He is an
editorial board member of the journals Analytical Biochemistry, BioTechniques, and Insight. Dr. Merril
also served as the Editor-in-Chief of Applied and Theoretical Electrophoresis and was the Senior
Associate Editor of the journal Electrophoresis. He has served as President of both the International
Electrophoresis Society and the American Electrophoresis Society and as Chairman of the Surgeon
General’s Advisory Panel for the Research Officer Group.
Oleg Sukonko, M.D.
Oleg Sukonko, M.D. is Director of N.N.Alexandrov National Cancer Centre of Belarus in Minsk and Chief
Oncologist of Belarusian Health Ministry. He is Professor of Oncology and author of more than 250
scientific papers in medical journals, 2 monographs and 4 patents. Prior to his current position Prof.
8
Cancer Detection Services
PC Detect®
Sukonko has worked as a Head of Urological Department in National Cancer Centre of Belarus from
1992 to 2010. During this time he devoted his scientific career to improvement in treatment efficacy of
genitourinary malignancies, particularly renal cell carcinoma. He has led a number of clinical studies on
surgical, immunological, multimodal therapy and hyperthermia of advanced renal cell carcinoma. He is
an active member of Belorussian Society of Oncology, Belorussian Urological Association, Russian
Society of Oncourology, European Association of Urology, American Urological Association and Société
Internationale d’Urologie. He is Editor-in-Chief of Oncologicheskij Journal (Belarus) and a member of
editorial board of official journal of Russian Society of Oncourology Oncourologija.
Michael S. Lebowitz, Ph.D.
Michael S. Lebowitz, Ph.D. has been the Director of Research at Panacea Pharmaceuticals since 2004.
Dr. Lebowitz joined the Company in 2000 as a Staff Scientist and was then promoted to Director,
Parkinson’s Disease Program and Project Leader, HAAH Oncology Therapeutics in early 2002. He
received his Ph.D. from the Johns Hopkins University School of Medicine in Biochemistry, Cellular, and
Molecular Biology. Subsequently, he completed a three year fellowship in immunology in the
Department of Pathology, Division of Immunopathology also at the JHU School of Medicine. Dr.
Lebowitz is also currently an adjunct Lecturer in the Advanced Academic Program in Biotechnology at
the Krieger School of Arts and Sciences, JHU. Prior to joining Panacea Pharmaceuticals, Dr. Lebowitz
was a research scientist at Proteinix Corporation in Gaithersburg, Maryland where he was involved in
the development of compounds for the control of ubiquitin-dependent protein degradation. He has
published numerous articles and abstracts in the fields of enzymology, cellular immunology, cancer, and
neurodegenerative disease. He is also an inventor on several patents and has served as a principal
investigator on several NIH-funded SBIR grants.
Steven Fuller PhD.
Dr. Fuller joined Panacea Pharmaceuticals in 2007 and serves as Vice President, Product Development.
Steven has over 23 years of experience in the pharmaceutical and biotechnology industries working on
a range of therapeutic and diagnostic products. Most recently Dr. Fuller served as Vice President,
Product and Process Development at Nabi Biopharmaceuticals, Inc. While at Nabi, he held positions of
increasing responsibility including Senior Director, Product Development and Product Development
Director. At Nabi, Dr. Fuller filed a biologics license application (Common Technical Document) for a
Staph aureus vaccine product in the EU, a biologics license application for a immune globulin product in
the US, and Investigation New Drug (IND) applications for four vaccine products and one other
therapeutic product. At ADI Diagnostics, Dr. Fuller was a Senior Research Scientist, Program Manager
and Director of Operations; ADI Diagnostics is a diagnostics manufacturer and distributor specializing in
cancer and infectious disease assays. He is author of numerous peer-reviewed publications and one
patent. Dr. Fuller received his B.S. degree in Biology from Wheaton College and his Ph.D. in genetics
from Michigan State University. He is a member of the American Society for Microbiology and the
American Association for Laboratory Animal Science.
Homayon Zehtab MD
He continued his education in reconstructive and aesthetic surgery in Tehran University of Medical
Sciences. Dr. Zehtab has many years of experience in teaching medical students, interns, residents and
fellows on general and plastic surgery. Dr. Zehtab is the chief of plastic surgery department in Taleghani
Hospital, Jundishapour University. He is an active member of Iranian society of General Surgeons,
Iranian society of Plastic Surgeons and West Asian society of plastic surgeons. Dr. Zehtab has
participated in many national and international plastic surgery conferences as a panelist, and lecturer.
Dr. Zehtab has published many articles about many different types of flaps, breast cancer reconstruction
using tram flaps and reconstruction of facial bones in Thalassemia patients. Currently he is the chief of
plastic surgery of Apadana General Hospital, N.I.O.C. Hospital as well as founder and CEO of Pars
Surgery Center in Ahvaz/Iran.
Chandra J. Panchal, Ph.D.
Chandra Panchal obtained a B.Sc. (1972) and a M.Sc., in Molecular Biology (1974) from the University
of Toronto, and a Ph.D., in Biochemical Engineering from the University of Western Ontario (1979).Dr.
Panchal is presently President & CEO at Axcelon Biopolymers Corporation, of London, Ontario, and
Managing Director of Panford Investment Corp of Montreal. From 1989-1999 he was Co-founder,
9
Cancer Detection Services
PC Detect®
President, and CEO of Procyon Biopharma Inc., and from1999-2006 he was Chief Scientific Officer and
Senior Executive VP. From 2006 to 2008 he was Executive VP, Business Development, Licensing &
Intellectual Property, at Ambrilia Biopharma Inc., which was a merger between Procyon and Cellpep
Inc., of France. Prior to co-founding Procyon, Dr. Panchal was a senior scientist/group leader
supervising activities related to yeast genetics, fermentation and product development at John Labatt
Ltd., a multinational food and beverage company. Dr. Panchal has authored over 50 scientific papers
and has edited a book entitled Yeast Strain Selection, published in 1990. Dr. Panchal has been on the
editorial board of the Canadian Journal of Microbiology and is a co-inventor in respect of several patents
in oncology, diagnostics and industrial microbiology. Dr. Panchal is an Adjunct Professor in Chemical
and Biochemical Engineering at the University of Western Ontario. He currently sits on the Boards of:
Chemaphor (TSX.V: CFR), Canadian Oil Recovery and Remediation Inc.,(CORRE; TSX.V:CVR),
Cardiogenics Inc.,(NASDAQ BB:CGNH.OB) Rodocanachi Capital Pool Company (TSX.V.ROD.P), and
MaRS Innovation.
Ladan Shariat MD,
Ladan Shariat MD, Radiologist (Iran), ARDMS, CARDAP (Canada): Dr. Ladan Shariat, has been
practicing medicine for many years as consulting MD for Yazd Allied Health Medical Center, Behafarin
Diagnostic radiology Medical Center, Shariat Radiology and Ultrasound Center, and Sarem Hospital as
Head of Diagnostic Radiology Department and Radiology in chief. Dr. Shariat has extensive experience
in practicing medicine , MRI, CT Scan and Ultrasound in Iran, in addition to her observary experience in
MRI and CT Scan fellowship in Toronto University Hospitals. Dr. Shariat is the Vice President of
Panacea Imaging Canada Inc., and advisory board member in Panacea Global Inc and Panacea
Laboratories Canada Inc. Dr. Shariat has received her MD from Beheshti University of Medical Sciences
and her Radiology specialty from Tehran Medical School, 1995.
Zahra Shariat Pharm.D
Dr. Zahra Shariat has studied pharmacy at Azad University of Tehran/Iran and was graduated in 1994.
Since 1994 to 2007 she practiced as clinical pharmacist at Fayazbakhsh Hospital, which is one of the
largest hospitals in Tehran. Dr. Shariat was the pharmacist in chief and technical officer in charge,
in Shariat Pharmacy in Tehran from 1997 to 2006. Dr. Shariat is an advisory Board member in Panacea
Global Inc and Panacea Imaging Canada Inc.
Saied Babaei MBA MD
Over 15 years of global business and multi-disciplinary scientific experience in biopharma, President &
CEO of AbCelex Technologies Inc. Previously held senior roles at Northern Therap; Vasogen; United
Therap; and Lorus Therap. Extensive experience in establishing strategic alliances, licensing deals, joint
ventures, private and public financing . Dr. Babaei also layed a key role in market launch of two
biopharmaceutical products in Canada.
Aras Azadian MBA, B.Econ
Aras Azadian is a strategic senior consultant at Panacea Global. Subsequent his graduation from an
International MBA program at EADA Barcelona Aras has been working as a consultant in financial and
pharmaceutical industries.
Yuri Lawryshyn, Ph.D
Yuri Lawryshyn completed a Ph.D. degree in engineering at the University of Toronto specializing in
Computational Fluid Dynamics (CFD), an MBA degree at the Richard Ivey Business School (UWO) and
a Financial Engineering diploma at the Schulich School of Business. He has worked in a number of
industries in research and development, management, marketing and strategy. In 2007, he joined the
faculty of Engineering at University of Toronto, specializing in applying financial engineering principles
for the valuation of real assets/projects, with specific emphasis in the development of practical
approaches to real options.
10
Cancer Detection Services
PC Detect®
Press Releases and News Coverage
11
Cancer Detection Services
PC Detect®
HAAH Scientific Publications and Abstracts
Publications
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
Nedim Ince, Suzanne de la Monte, Jack R. Wands. “Overexpression of Human Aspartyl (Asparaginyl) β-Hydroxylase is associated
with malignant transformation.” Cancer Research: 60, 1261-1266, 2000.
Eric T. Boder, Katarina D. Midelfort, and K. Dane Wittrup. “Directed evolution of antibody fragments with monovalent femtomolar
antigen-binding affinity.” Proceedings of the National Academy of Sciences: 97(20), 10701-10705, 2000.
Sepe PS, Lahousse SA, Gemelli B, Chang H, Maeda T, Wands JR, de la Monte SM. “Role of the aspartyl-asparaginyl-betahydroxylase gene in neuroblastoma cell motility.” Lab Invest J: 82(7):881-91, 2002.
Palumbo KS, Wands JR, Safran H, King T, Carlson RI, de la Monte SM. “Human aspartyl (asparaginyl) beta-hydroxylase
monoclonal antibodies: potential biomarkers for pancreatic carcinoma.” Pancreas Jul; 25(1):39-44, 2002.
Commentary on Wittrup paper. “Breaking the Affinity Ceiling for Antibodies and T Cell Receptors.” Proceedings of the National
Academy of Sciences: 97(20), 10679-1068, 2000.
Michael J. Feldhaus, Robert W. Siegel, et al. „Flow-cytometric isolation of human antibodies from a non-immune Sacchoromyces
cerevisiae surface display library.” Nature Biotechnology: 21, 163-170, 2003.
Takashi Maeda, Paul Sepe, Stephanie Lahousse, Seishu Tamaki, Munetomo Enjoji, Jack R. Wands, and Suzanne M. de la Monte.
“Antisense Oligodeoxynucleotides Directed Against Aspartyl (Asparaginyl) ß-Hydroxylase Suppress Migration Of
Cholangiocarcinoma Cells.” Journal of Hepatology: 38, 615-622, 2003.
Gregory J. Gores. Editorial: “Cholangiocarcinoma: Preventing Invasion as Anti-Cancer Strategy.” Journal of Hepatology 38, 671673, 2003.
Eric P. Berthiaume, M.D., and Jack Wands, M.D. “The Molecular Pathogenesis of Cholangiocarcinoma.” Seminars in Liver Disease
24(2): 127-137, 2004.
Takashi Maeda, Ken-ichi Taguchi, Shin-ichi Aishima, Mitsuo Shimada, Deborah Hintz, Nicholas LaRusso, Gregory Gores,
Masazumi Tsuneyoshi, Keizo Sugimachi, Jack R. Wands, and Suzanne de la Monte. “Chinicopathological Correlates of Aspartyl
(Asparaginyl) β-Hydroxylas Over-Expression in Cholangiocarcinoma.” Cancer Detection and Prevention: 28, 313-318, 2004.
Suzanne M. de la Monte, Seishu Tamaki, M. Chiara Cantarini, Nedim Ince, Marcus Wiedmann, Jade J. Carter, Stephanie A.
Lahousse, Sophia Califano, Takashi Maeda, Takato Ueno, Antonia D’Errico, Franco Trevisani, Jack R. Wands. “Aspartyl(asparaginyl)-β-hydroxylase Regulates Hepatocellular Carcinoma Invasiveness.” Journal of Hepatology: 44, 971-983, 2006.
Zhi-Hong Xian, Shu-Hui Zhang, Wen-Ming Cong, He-Xin Yan, Kui Wang, and Meng-Chao Wu. “Expression of aspartyl betahydroxylase and its clinicopathological significance in hepatocellular carcinoma.” Modern Pathology 19: 280-286, 2006.
G. Feldmann, J. Nattermann, H.D. Nischalke, M.Gorschluter, T. Kuntzen, G. Ahlenstiel, G. Ahlenstiel, T. Gerhardt, M. Wolff, T.
Sauerbruch, U. Spengler, F.L. Dumoulin. “Detection of Human Aspartyl (Asparaginyl) Beta-Hydroxylas and Homeobox B7 mRNA in
Brush Cytology Specimens from Patients with Bile Duct Cancer.” Endoscopy, 38:6, 604-609, 2006.
M.Chiara Cantarini, Suzanne M. De la Monte, Maoyin Pang, Ming Tong, Antonia D’Errico, Franco Trevisani and Jack R. Wands.
“Aspartyl-Asparagyl β hydroxylase Over-Expression in Human Hepatoma is Linked to Activation of Insulin-Like Growth Factor and
Notch Signaling Mechanisms.” Hepatology, 44:2, 446-457, 2006.
Stephanie A. Lahousse, Jade J. Carter, Xaolai J. Xu, Jack R. Wands and Suzanne M. de la Monte. Differential growth factor
regulation of Aspartyl-Asparagyl β hydroxylase family genes in SH-Sy5y human neuroblastoma cells. BMC Cell Biology, 7:41, 1-21,
2006
WO01/35102-PCT/US00/30738: “Diagnosis and Treatment of Malignant Neoplasms”; filed November 8, 2000.
US Patent 6,783,758: "Diagnosis and Treatment of Malignant Neoplasms"; Issued: August 31, 2004
US Patent 6,797,696: "Diagnosis and Treatment of Malignant Neoplasms"; Issued: September 28, 2004.
US Patent 6,812,206: "Diagnosis and Treatment of Malignant Neoplasms"; Issued: November 2, 2004.
US Patent 6,815,415: "Diagnosis and Treatment of Malignant Neoplasms"; Issued: November 9, 2004
US Patent 6,835,370: "Diagnosis and Treatment of Malignant Neoplasms"; Issued: December 28, 2004
US Patent 7,094,556: "Diagnosis and Treatment of Malignant Neoplasms"; Issued: August 22, 2006.
Abstracts
1.
2.
3.
4.
5.
S. Lahousse, P. Sepe, J. R. Wands, and S. M. de la Monte. Role of Aspartyl (Asparaginyl) β-Hydroxylase in Neuroblastoma
Migration. 90th Annual Meeting of the United States & Canadian Academy of Pathology, Atlanta, Georgia, March 7, 2001.
Kevin Scott Palumbo, Thomas King, Howard Safran, Jack R. Wands, Suzanne de la Monte. Potential Biomarkers for Detecting
Pancreatic Carcinoma. Gastroenterology: 120, Number 5, A-161, 2001.
Michael A. Rosen, Kasra Ghanbari, Alan H. Deutch, and Hossein A. Ghanbari. Development of Cancer Immunodiagnostics Using
Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) as a Biomarker. AACR-NCI-EORTC International Conference, Molecular
Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, October 29-November 2, 2001, Miami Beach,
Florida.
Michael S. Lebowitz, Angela H. Finney, Valery M. Nelson, Audrey A. Vasauskas, Kasra Ghanbari, Alan H. Deutch and Hossein A.
Ghanbari. Inhibition of Cancer Cell Proliferation, Motility and Invasiveness by Monoclonal Antibodies Specific for Human Aspartyl
(Asparaginyl) β-Hydroxylase (HAAH). AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics:
Discovery, Biology, and Clinical Applications, October 29-November 2, 2001, Miami Beach, Florida.
Wands, Jack R.; Tamaki, Seishu; Sepe, Paul; Maeda, Takashi; Lahousse, Stephanie; and de la Monte, Suzanne M. Antisense
Oligonucleotide of Human Aspartyl (Asparaginyl) β-Hydroxylase Suppresses Migration of Human Cholangiocellular Cells. American
12
Cancer Detection Services
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
PC Detect®
Association for The Study of Liver Diseases - 52nd Annual Meeting November 9-13, 2001 Hepatology,: 34(4), Part II, pp. 267A,
October 2001.
Lawrence Glass, Kasra Ghanbari, Michael S. Lebowitz, and Hossein A. Ghanbari. Differential Expression of ASPH Gene Encoding
Human Aspartyl (Asparaginyl) β-Hydroxylase in Cancer Versus Normal Tissues. AACR 94th Annual Meeting, July 11-14 2003,
Washington, DC.
Audrey A. Vasauskas, Cyra M. Ranji, Kasra Ghanbari, Michael S. Lebowitz, and Hossein A. Ghanbari. Human Aspartyl
(Asparaginyl) β-Hydroxylase is a Serum Biomarker of Breast, Ovarian, and Prostate Cancer. AACR 94th Annual Meeting, July 11-14
2003, Washington, DC.
Vasauskas, A.A., Glass, L., Ghanbari, K., Lebowitz, M.L., Ranji, C., Maric, M., and Ghanbari, H.A.: “HAAH as a Biomarker for
Pancreatic Adenocarcinoma Using IHC, qRT-PCR and ELISA.” AACR—Molecular Targets and Cancer Therapeutics Meeting,
November 17-21, 2003, Boston, MA.
Finney, A.H., Lebowitz, M.L., Vasauskas, A.A., Ghanbari, K., Nelson, V.M., and Ghanbari, H.A.: “Anti-Proliferative and AntiMetastatic Activities of Monoclonal Antibodies to Human Aspartyl (Asparaginyl) β-Hydroxylase.” AACR—Molecular Targets and
Cancer Therapeutics Meeting, November 17-21, 2003, Boston, MA.
Yeung, A., Finney, A.H., Lebowitz, M.L., Ghanbari, K., Ghanbari, H.A., Wittrup, D.: “Isolation and Engineering of Biologically Active
Human Single-Chain Antibody Fragments (Scfv) Against Human Aspartyl (Asparaginyl) β-Hydroxylase.” AACR—Molecular Targets
and Cancer Therapeutics Meeting, November 17-21, 2003, Boston, MA
A.H. Finney, M.W. D’Amico, S.F. Roberts, M.S. Lebowitz, H.A. Ghanbari. Surface Expressed HAAH in Cancer Cells is an
Internalizing Antigen. AACR 97th Annual Meeting, Washington, D.C. 2006
Nelson, V.M., Finney, A.H., Drape, R.J., Bleck, G.T., Lebowitz, M.L., Ghanbari, H.A. “Manufacture of anti_HAAH Antibodies as
Potential Human Therapeutics.” 1st AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development,
Chicago, IL (2006)
Lebowitz, M.L., Otahalova, E., Ghanbari, H.A. “A Novel Biomarker to Diagnose and Monitor Acute Myelogenous Leukemia.” 1st
AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Chicago, IL (2006)
Ghanbari, H.A., Vasauskas, A.A., Bensmail, I., Lebowitz, M.L. “HAAH is a Serum Biomarker for Prostate Cancer.” 1st AACR
International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Chicago, IL (2006)
Otahalova, E., Lebowitz, M.L., Ghanbari, H.A. “Identification of Responders and Non-Responders to Imatinib Prior to Treatment.”
18th EORTC-NCI-AACR International Conference on “Molecular Targets and Cancer Therapeutics, Prague, Czech Republic (2006)
D’Amico, MD; Roberts, SF; Lebowitz, MS; Ghanbari, HA. Use of anti-HAAH antibodies in cancer therapy: specific delivery of
cytotoxic agents. AACR Annual Meeting 2007, Los Angeles, CA (2007)
Semenuk, M; Repoli, AF; Lebowitz, MS; Harris, PJ; Ghanbari, HA. HAAH is a Serum Biomarker for Lung Cancer. The Second
Annual AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for
Personalized Treatment, Atlanta, GA (2007)
Ghanbari, HA; Repoli, AF; Semenuk, M; Harris, PJ; Lebowitz, MS. HAAH as a Serum Biomarker for Breast Cancer. An AACR
Special Conference in Cancer Research―Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, San
Diego, CA (2007)
H.A. Ghanbari, A.F. Repoli, M. Semenuk, P.J. Harris and M.S. Lebowitz. HAAH as a serum biomarker for colorectal cancer. An
AACR Special Conference in Cancer Research―Advances in Colon Cancer Research Cambridge, MA (2007)
S.N. Keith, P.J. Harris, A.F. Repoli, M. Semenuk, H.A. Ghanbari and M.S. Lebowitz. The Serum Biomarker HAAH Identifies
Prostate Cancer In Individuals With Low PSA Values. 2008 Genitourinary Cancers Symposium. San Francisco, CA. (2008)
Michael S. Lebowitz, Angela F. Repoli, Mark Semenuk, Ilham Bensmail and Hossein A. Ghanbari. “Integration of the Cancer
Biomarker, HAAH, into a Companion Diagnostic Strategy.” Oncology Biomarkers: From Discovery to Validation. San Francisco, CA
(2008)
Hossein Ghanbari, Valery Nelson, Angela F. Repoli, and Michael S. Lebowitz. “PAN-622, An All-Human Anti-Cancer Antibody Drug
Candidate Targeted to HAAH: A Cytostatic Approach to Cancer Therapy. International Congress on Anti Cancer Treatment, Paris,
France. (2008)
Hossein Ghanbari, Angela F. Repoli, Mark Semenuk, Ilham Bensmail, Audrey A. Vasauskas and Michael S. Lebowitz. “HAAHbased Serum Cancer Test: A Companion Diagnostic in Cancer Therapeutics.” International Congress on Anti Cancer Treatment,
Paris, France. (2008)
Hossein A. Ghanbari and Michael S. Lebowitz. “In vivo efficacy of PAN-622: An All Human Sequence Monoclonal Antibody
Targeted at HAAH.” AACR Annual Meeting 2008, San Diego, CA (2008)
Ilham Bensmail, Michael S. Lebowitz and Hossein A. Ghanbari. “Anti-HAAH antibodies block leukemic cell activity via downregulation of the Notch signaling pathway.” AACR Annual Meeting 2008, San Diego, CA (2008)
26. D. Khayat, R. Mouawad, M. S. Lebowitz, and H. A. Ghanbari. “Serum HAAH Level in NSCLC is a
Diagnostic and Could be a Predictive Factor of Clinical Response.” 44th ASCO Annual Meeting, Chicago, IL (2008).
27. Biswajit Biswas, Marjan Alaghmand, Illham Bensmail, Carl Meril, and Hossein A. Ghanbari.”Dentritic Cell-Based Center
Therapeutic Vaccine targeting HAAH Using nano-Particles To Overcome Tolerance and Avoid Auto-Immune
Response.” International Society for Biological Therapy of Cancer (ISBTc) 25th Annul Meeting, Bethesda, MD( 2009)
13
Cancer Detection Services
PC Detect
28. H. Ghanbari, M. Moshiri ,*, M. S. Lebowitz , S. F. Roberts , A. Zokaei-Ashtiani, C. J. Panchal,
“HAAH-BASED MONITORING OF CANCER REMISSION/RECURRENCE, World Cancer Congress,UICC, Montreal,
ON, Canada, (2012).
29. M. Moshiri, M. S. Lebowitz , S. F. Roberts 2, C. J. Panchal, A. Zokaei-Ashtiani, H. Ghanbari
“EARLY DIAGNOSIS OF CANCER: HAAH-BASED SERUM IMMUNOASSAY”, 2012-World Cancer Congress, UICC,
Montreal, ON, Canada, (2012).
14
P
G
330 Highway 7 East. Suite 502,
Richmond Hill, On, Canda, L4B 3P8
Tel:
905.881.1049
905.881.3624
Fax: 905.881.2241
Website: www.panaceaglobalinc.com
A division of Panacea Pharmaceuticals, Inc.
Only a physician can order these tests.
A positive test result may be due to other cancers or occasionally may have unknown causes.
Panacea Laboratories developed BC DetectSM and has determined its analytical performance
characteristics. Panacea Laboratories is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) to perform high-complexity testing. LC Detect is intended to be used for clinical purposes.
Other serum-based tests also available from Panacea Laboratories are PC Detect® for prostate cancer
screening, LC DetectSM for lung cancer screening, and CC DetectSM for detection of colorectal cancer
screening.